Sign in

Jacob S. Aday

@jacobsaday.bsky.social
809 followers 178 following 34 posts

Experimental psychologist researching psychedelics at UMich | Michigan Psychedelic Center (M-PsyC) | Chronic Pain and Fatigue Research Center (CPFRC) | he/him scholar.google.com/citations?user=g…

PostsRepliesMedia
Reposted by Jacob S. Aday
Johns Hopkins Psychedelic Research Center @jhpsychedelics.bsky.social · 16/09/2026
Psychedelics are not risk-free. See our PSA video below. In recreational settings, risks can include panic, impaired judgment, worsening of psychiatric symptoms, and persistent perceptual changes, all of which can be compounded by unknown dosing.
131
Reposted by Jacob S. Aday
Samuli Kangaslampi @kangaslampi.bsky.social · 29/04/2026
Out today in Psychopharmacology: Our scoping review on recovery of repressed memories under psychedelics, spearheaded by Anne-Fiona Griesfeller and Lotte Kooman: doi.org/10.1007/s002...
doi.org
Evaluating the evidence for repressed memory recovery in psychedelic contexts - Psychopharmacology
Rationale Reports of resurfaced repressed memories during psychedelic experiences have circulated for decades and still emerge today. However, the veracity of repressed memories remains debated, and the mechanisms through which psychedelics might recover alleged repressed memories are unclear. Objectives This scoping review aimed to provide an overview of the literature on repressed memory in the context of psychedelics. It examined how repressed memory was defined, which substances were predominantly discussed, which mechanisms were proposed to explain their effects, and whether these mechanisms were empirically supported. Methods A scoping review was conducted in line with PRISMA-ScR guidelines. Web of Science, PubMed, PsycINFO and Google Scholar were searched for relevant publications. Fifty-three sources met eligibility criteria. Data were charted on study design, psychedelic substance, definitions of repressed memory, results, and proposed mechanisms. Results Most publications focused on lysergic acid diethylamide (LSD) in relation to repressed memory. Few sources provided a definition of repressed memory. Proposed mechanisms on how psychedelics might influence repressed memory included psychoanalytical reductions of defensive memory blockades and neurobiological alterations of executive control. However, empirical support for these mechanisms was limited. Conclusions The included literature did not offer a coherent explanation on how psychedelics could recover repressed memories, nor consistent evidence that they did so reliably. Future work should provide clear definitions of repressed memory in the context of psychedelics, test proposed effects of psychedelics on memory and executive control across multiple psychedelic substances, include placebo-controlled designs, and account for the potential occurrence of false memories.
121
Reposted by Jacob S. Aday
Bertoglio lab (FMC/UFSC) @bertogliolab.bsky.social · 09/02/2026
Preliminary effects of ayahuasca on mental and physical health: A systematic review of prospective studies www.sciencedirect.com/science/arti...
sciencedirect.com
Preliminary effects of ayahuasca on mental and physical health: A systematic review of prospective studies
Ayahuasca is a psychedelic plant brew that has been used in Central and South America for centuries. Recently, there has been an increase in “drug tou…
021
Jacob S. Aday @jacobsaday.bsky.social · 04/02/2026
"Blunted Psychedelic Drug Effects in Older Adults", coauthored with @robincarhartharris.bsky.social and Kevin Boehnke, is out now in the American Journal of Geriatric Psychiatry.
100
Jacob S. Aday @jacobsaday.bsky.social · 19/12/2025
“D-M-T” but to the tune of “TNT” by AC/DC
130
Jacob S. Aday @jacobsaday.bsky.social · 03/12/2025
New paper from the Michigan Psychedelic Center (M-PsyC) and collaborators! "Best practices for first psychedelic experiences: Harm reduction advice from the psychedelic community"
020
Reposted by Jacob S. Aday
Bertoglio lab (FMC/UFSC) @bertogliolab.bsky.social · 26/11/2025
Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community link.springer.com/article/10.1...
link.springer.com
Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community - Harm Reduction Journal
Background The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeutic applications of psychedelics may result in a record number o...
011
Reposted by Jacob S. Aday
D. Parker Kelley, PhD @sequencemyneuro.bsky.social · 20/10/2025
🚨Publication alert! 🚨 Why does stress drive psychopathology & transdiagnostic disease? We present the Allostatic Triage Model of Psychopathology (ATP Model), which explains stress-induced transdiagnostic disease pathogenesis through a bioenergetic lens. www.sciencedirect.com/science/arti...
5148
Reposted by Jacob S. Aday
Tyler Ekins @tylerekins.bsky.social · 13/08/2025
Our latest manuscript (from www.omarlab.org) is now published and available online -- Long lasting enhancement in reversal learning after a single psychedelic dose pmc.ncbi.nlm.nih.gov/articles/PMC...
pmc.ncbi.nlm.nih.gov
Single-dose psychedelic enhances cognitive flexibility and reversal learning in mice weeks after administration
Psychedelic compounds have demonstrated remarkable therapeutic potential for treating neuropsychiatric disorders by promoting sustained neuroplasticity in the prefrontal cortex (PFC). Cognitive flexib...
061
Reposted by Jacob S. Aday
Max Wolff @trpwolff.bsky.social · 16/06/2025
Reframing Psychedelic Regulation: Tools, not Treatments In this new article, we propose to regulate psychedelics as psychotherapeutic treatment tools rather than as treatments in their own right. The use of anesthetics as treatment tools in surgery is a useful analogy.
Drug Science, Policy and Law
Screenshot of title page and abstract
2248
Reposted by Jacob S. Aday
Max Wolff @trpwolff.bsky.social · 14/05/2025
Last year, @jacobsaday.bsky.social and @trpr-ucsf.bsky.social asked: "Psychedelic assisted psychotherapy: where is the psychotherapy research?" link.springer.com/article/10.1... How soon can we say "here it comes"?
link.springer.com
Psychedelic-assisted psychotherapy: where is the psychotherapy research? - Psychopharmacology
Rationale Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use disorders and depression. Current models of P...
1103
Reposted by Jacob S. Aday
Jules Evans @philosojules.bsky.social · 28/04/2025
Psychedelics could play a leading role in mental health care. But if approval is rushed without necessary guardrails in place, there will be a backlash, and these drugs will be relegated to the fringes of alternative health. That would be a tragic missed opportunity. www.nytimes.com/2025/04/28/o...
nytimes.com
Opinion | How the American Right Learned to Love Psychedelics (Gift Article)
A once left-wing psychedelic movement has become tightly entwined with the Trump administration.
2165
Reposted by Jacob S. Aday
David Yaden @existwell.bsky.social · 15/04/2025
🚨 Postdoc Opportunity in Psychedelic Science Join a leading psychedelic research team at Johns Hopkins @jhpsychedelics.bsky.social. Design and lead experimental studies & clinical trials. Work with David Yaden, PhD & Sandeep Nayak, MD & others -Salary: Middling -Apply: dyaden1@jh.edu -Pls share!
0114
Jacob S. Aday @jacobsaday.bsky.social · 17/04/2025
“Addressing blinding in classic psychedelic studies with innovative active placebos” is out now in the International Journal of Neuropsychopharmacology. Co-first authored with Otto Simonsson, alongside Cyril D’Souza and Emmanuelle Schindler academic.oup.com/ijnp/advance...
academic.oup.com
Addressing blinding in classic psychedelic studies with innovative active placebos
AbstractRationale. Classic psychedelics show promise as a treatment for various neuropsychiatric disorders. However, weak blinding integrity in trials has
160
Reposted by Jacob S. Aday
Daniel J. Kruger @danielkruger.bsky.social · 07/04/2025
We are thrilled to announce the launch of the 2025 Psychedelic Community Survey, a research project for the psychedelic community. Participation is completely anonymous. Please share the survey invitation and link with anyone you think might be interested in participating.
umich.qualtrics.com
Understanding experiences with psychedelics
The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.
043
Reposted by Jacob S. Aday
Eirini K Argyri @eirini-k-a.bsky.social · 07/04/2025
New pre-print out 🌍✨🌌 'Learning from Boundlessness: Psychedelic induced awe and epistemic shifts towards a holistic worldview' doi.org/10.21203/rs.... We explored how awe during psychedelic experiences relates to lasting shifts in sense of self, other, and reality
doi.org
Learning from Boundlessness: Psychedelic induced awe and epistemic shifts towards a holistic worldview
Psychedelic substances are increasingly recognized for their potential to catalyse transformative shifts in worldviews. Central to these transformations are states of awe, a self-transcendent, epistem...
143
Jacob S. Aday @jacobsaday.bsky.social · 18/03/2025
Our pilot clinical trial of psilocybin-assisted therapy for fibromyalgia was published today in Frontiers in Pain Research 🙂🍄 www.frontiersin.org/journals/pai...
frontiersin.org
Frontiers | Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial
1113
Reposted by Jacob S. Aday
Bryan Roth @zenbrainest.bsky.social · 19/02/2025
My lab has a position for a programmer--if you have programming skills and have recently left the NIH please contact me.
16379
Reposted by Jacob S. Aday
Daniel J. Kruger @danielkruger.bsky.social · 12/02/2025
Newest paper: #PsychedelicScience #Psychedelics
tandfonline.com
Tripping into Treatment: Comparing Initial and Current Motivations for Psychedelic Use
Psychedelic drugs are currently being explored for their therapeutic potential for a variety of health conditions. The recent increased public interest in psychedelics necessitates empirical invest...
022
Jacob S. Aday @jacobsaday.bsky.social · 11/02/2025
New articles from the Michigan Psychedelic Center: "Tripping into Treatment: Comparing Initial and Current Motivations for Psychedelic Use" "Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use"
184
Reposted by Jacob S. Aday
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 02/02/2025
Just came across this fascinating 2024 DMT study I missed - participants who were interrupted during their DMT experience (by having to give ratings) showed significantly less reduction in depressive symptoms compared to those left undisturbed. Important implications for psychedelic therapy. 🧵
3258
Reposted by Jacob S. Aday
josh hardman @josh-hardman.bsky.social · 10/01/2025
Latest twist in Lykos saga has it all: ✅ Takeover bid led by billionaire who took drugs with Elon + helped him buy X ✅ Potential involvement of biotech exec widely accused of price gouging ✅ But also the potential to return Lykos to its public benefit mission psychedelicalpha.com/news/billion...
psychedelicalpha.com
Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing - Psychedelic Alpha
This latest twist in the Lykos Therapeutics saga threatens a major overhaul of the company’s strategy and direction, with Musk ally and billionaire investor Antonio Gracias appearing to want to take…
0123
Reposted by Jacob S. Aday
D. Parker Kelley, PhD @sequencemyneuro.bsky.social · 08/01/2025
Big co-1st/corresponding author paper just published in @JAMAPsychiatry! I just can't thank our team enough for their unwavering support on this project. Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials jamanetwork.com/journals/jam...
jamanetwork.com
Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials
This narrative review describes clinical trials of psychedelic or MDMA therapy and reports from the investigators on the use of modifications to informed consent in these studies.
2126
Reposted by Jacob S. Aday
josh hardman @josh-hardman.bsky.social · 05/12/2024
I spoke with Javier Muniz, MD, who just left his role as Associate Director at FDA's Division of Psychiatry, about all things psychedelics. psychedelicalpha.com/news/inside-...
psychedelicalpha.com
Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges, and the Future of the Field - Psychedelic Alpha
In our latest Pα+ interview, our Editor Josh Hardman speaks with Javier Muniz, MD, who recently left his post as Associate Director at the FDA’s Division of Psychiatry. In that role, Muniz was at the…
294
Reposted by Jacob S. Aday
Suresh Muthukumaraswamy @sdmuthu.bsky.social · 29/11/2024
Psychopharmacology gets lots of criticism from psychotherapy/adjacent folks. But if someone could send me therapy trials that 1. Are double-triple blind 2. Carefully document/report AEs 3. Pre-register an SAP with ITT I would appreciate. I will wait ….
4112
Jacob S. Aday @jacobsaday.bsky.social · 20/11/2024
A new preprint for my new BlueSky homies: "Major life changes following psychedelic use: A retrospective survey among people using psychedelics naturalistically" www.researchgate.net/publication/...
researchgate.net
(PDF) Major life changes following psychedelic use: A retrospective survey among people using psychedelics naturalistically
PDF | Background: Psychedelic drugs show promise in facilitating a variety of long-term psychological changes, but they may also lead to unexpected... | Find, read and cite all the research you need o...
74814